Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) saw an uptick in trading volume on Monday . 2,089,976 shares were traded during trading, an increase of 640% from the previous session’s volume of 282,616 shares.The stock last traded at $1.57 and had previously closed at $1.46.
A number of brokerages recently issued reports on PSTI. Zacks Investment Research upgraded Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 22nd. Maxim Group set a $3.00 price objective on Pluristem Therapeutics and gave the company a “buy” rating in a research note on Wednesday, February 21st. HC Wainwright set a $4.00 price objective on Pluristem Therapeutics and gave the company a “buy” rating in a research note on Tuesday, January 16th. Finally, ValuEngine downgraded Pluristem Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Pluristem Therapeutics currently has an average rating of “Hold” and an average price target of $4.00.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. ARK Investment Management LLC lifted its holdings in Pluristem Therapeutics by 363.5% in the 4th quarter. ARK Investment Management LLC now owns 290,922 shares of the biotechnology company’s stock worth $401,000 after purchasing an additional 228,149 shares in the last quarter. Jane Street Group LLC lifted its holdings in Pluristem Therapeutics by 15.0% in the 3rd quarter. Jane Street Group LLC now owns 266,043 shares of the biotechnology company’s stock worth $402,000 after purchasing an additional 34,742 shares in the last quarter. Psagot Investment House Ltd. lifted its holdings in Pluristem Therapeutics by 1,705.2% in the 3rd quarter. Psagot Investment House Ltd. now owns 129,522 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 122,347 shares in the last quarter. Finally, Meitav Dash Investments Ltd. purchased a new position in Pluristem Therapeutics in the 4th quarter worth approximately $138,000. 4.28% of the stock is currently owned by institutional investors.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.